Effect of Post‐Ablational Angiotensin Receptor‐Neprilysin Inhibitor on Atrial Fibrillation Recurrence: A Systematic Review and Meta‐Analysis in Asian Population
Clinical Cardiology · 2026-04 · 49 (4)
DOI: 10.1002/clc.70284 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Clinical Cardiology, online erschienen am 06.04.2026. Verfasst von Yangyang Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Department of Cardiology, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, Henan, China. Hauptthemen laut MEDLINE: Atrial Fibrillation, Neprilysin, Angiotensin Receptor Antagonists, Catheter Ablation. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Henan Province.
Abstract (Originalsprache)
Background
The efficacy of angiotensin receptor‐neprilysin inhibitor (ARNI) in reducing recurrence risk of atrial fibrillation (AF) after ablation remains uncertain.
Methods
We summarized the results about ARNI in preventing AF recurrence after radiofrequency ablation. After PROSPERO registration, two researchers independently screened the literature and assessed the risk of bias in the included studies. The fixed effects model was used to merge the effect sizes, and the results were reported separately depending on whether the study was a RCT or a cohort study and on the follow‐up duration. We further conducted subgroup analysis by comparing the effect of ARNI in reducing AF recurrence to that of angiotensin‐converting enzyme inhibitor and/or angiotensin receptor blocker (ACEI/ARB) and to that of the Blank group. Publication bias and sensitivity analysis were evaluated.
Results
Both in RCTs and cohort studies, constant usage of ARNI for 6 and 12 months partly reduced the AF recurrence after ablation (using 3‐month ARNI in RCTs: RR = 0.56; 95% CI = 0.37–0.85; p = 0.006; using 6‐month ARNI in RCTs: RR = 0.57; 95% CI = 0.39–0.82; p = 0.003; using 12‐month ARNI in RCTs: RR = 0.65; 95% CI = 0.49–0.88; p = 0.005; using 6‐month ARNI in cohort studies: RR = 0.44; 95% CI = 0.32–0.61; p < 0.001). Subgroup analysis showed that, compared to ACEI/ARB or Blank, both in RCTs and cohort studies, ARNI was more effective in reducing the recurrence rate of atrial fibrillation after ablation.
Conclusions
The using of ARNI may be effective in preventing the recurrence of AF after ablation, with ARNIs being shown to be more effective than ACEI/ARBs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Department of Cardiology, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, Henan, China.
- The Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Västra Götaland County, Sweden.
- Greater Baltimore Medical Center, Towson, Maryland, USA.
ORCID-Profile: Yangyang Wang, Wenjing Zhang, Yunfei Gu, Hao Wang
Förderung
- Natural Science Foundation of Henan Province
Zitieren
APA
Wang, Y., Zhang, W., Shao, Y., Dong, Q., Gu, Y., & Wang, H. (2026). Effect of Post‐Ablational Angiotensin Receptor‐Neprilysin Inhibitor on Atrial Fibrillation Recurrence: A Systematic Review and Meta‐Analysis in Asian Population. Clinical Cardiology, 49(4). https://doi.org/10.1002/clc.70284
Vancouver
Wang Y, Zhang W, Shao Y, Dong Q, Gu Y, Wang H. Effect of Post‐Ablational Angiotensin Receptor‐Neprilysin Inhibitor on Atrial Fibrillation Recurrence: A Systematic Review and Meta‐Analysis in Asian Population. Clinical Cardiology. 2026;49(4). doi:10.1002/clc.70284
BibTeX
@article{Wang2026,
author = {Wang, Yangyang and Zhang, Wenjing and Shao, Yang and Dong, Qiming and Gu, Yunfei and Wang, Hao},
title = {Effect of Post‐Ablational Angiotensin Receptor‐Neprilysin Inhibitor on Atrial Fibrillation Recurrence: A Systematic Review and Meta‐Analysis in Asian Population},
journal = {Clinical Cardiology},
year = {2026},
volume = {49},
number = {4},
doi = {10.1002/clc.70284}
}
EUVIMED